[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Hueser CN, Nguyen NC, Osman M, Havlioglu N, Patel AJ: Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans. World J Surg Oncol; 2008;6:102
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans.
  • BACKGROUND: Extrapulmonary small cell carcinoma (EPSCC) involving the brain is a rare manifestation of an uncommon tumor type.
  • CASE PRESENTATION: We report a 59 year-old Caucasian female diagnosed with an EPSCC involving the left parietal lobe without detectable extracranial primary tumor followed by serial positron emission tomography/computed tomography (PET/CT) imaging.
  • Histopathological examination at both initial presentation and recurrence revealed small cell carcinoma.
  • CONCLUSION: Chemotherapy may show a transient response in the treatment of EPSCC.
  • Further studies are needed to help identify optimal treatment strategies.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Craniotomy. Female. Fluorodeoxyglucose F18. Humans. Middle Aged. Radiopharmaceuticals. Topotecan / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Nov 1;107(9):2262-9 [16998932.001]
  • [Cites] Recent Results Cancer Res. 2008;170:193-202 [18019627.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1194-204 [17962613.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):39-42 [17270664.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):30-8 [17270663.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):1-2 [17270659.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 5:v99-102 [16807475.001]
  • [Cites] J Korean Med Sci. 2006 Oct;21(5):833-7 [17043415.001]
  • [Cites] Neth J Med. 2000 Feb;56(2):51-5 [10710941.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):238-42 [10757334.001]
  • [Cites] Histopathology. 2000 May;36(5):415-20 [10792482.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1217-23 [10976695.001]
  • [Cites] Annu Rev Med. 2002;53:89-112 [11818465.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):1911-7 [14660716.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):250-4 [15231859.001]
  • [Cites] Ann Diagn Pathol. 2006 Apr;10(2):67-71 [16546039.001]
  • [Cites] South Med J. 2005 Mar;98(3):345-9 [15813162.001]
  • [Cites] Radiology. 2005 Jan;234(1):227-34 [15564390.001]
  • [Cites] Med Oncol. 1998 Apr;15(1):66-9 [9643534.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1366-72 [9338459.001]
  • [Cites] Cancer. 1997 May 1;79(9):1729-36 [9128989.001]
  • [Cites] Ann Oncol. 1994 Dec;5(10):909-13 [7696162.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):422-4 [1688727.001]
  • [Cites] Medicine (Baltimore). 1987 Nov;66(6):457-71 [2824968.001]
  • (PMID = 18817561.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7M7YKX2N15 / Topotecan
  • [Other-IDs] NLM/ PMC2564932
  •  go-up   go-down


2. Borri A, Leo F, Veronesi G, Solli P, Galetta D, Gasparri R, Petrella F, Scanagatta P, Radice D, Spaggiari L: Extended pneumonectomy for non-small cell lung cancer: morbidity, mortality, and long-term results. J Thorac Cardiovasc Surg; 2007 Nov;134(5):1266-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pneumonectomy for non-small cell lung cancer: morbidity, mortality, and long-term results.
  • In the present study, pneumonectomy may be associated with an extended resection of mediastinal or parietal structures.
  • The postoperative risk and the oncologic benefits of such an extended procedure have not been sufficiently demonstrated.
  • The "extended" procedure included left atrium resection in 15 patients, combined SVC and carinal resection in 9 patients, aortic resection in 8 patients (in 3 patients with prosthetic replacement), chest wall or diaphragmatic resection in 6 patients, SVC resection in 4 patients, and carinal resection in 4 patients.
  • Interestingly, long-term survivors were recorded only in the group of patients who received induction treatment.
  • CONCLUSIONS: Extended pneumonectomy is a feasible procedure with an acceptable risk factor.
  • To improve the selection of patients, all candidates should undergo preoperative mediastinoscopy and induction chemotherapy.
  • In patients with positive response to chemotherapy or stable disease, extended pneumonectomy may afford a radical resection in more than 80% of cases and may result in a permanent cure in some instances.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / statistics & numerical data
  • [MeSH-minor] Feasibility Studies. Female. Humans. Male. Middle Aged. Morbidity. Mortality. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976460.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Razzouk K, Roman H, Chanavaz-Lacheray I, Scotté M, Verspyck E, Marpeau L: Mixed clear cell and endometrioid carcinoma arising in parietal endometriosis. Gynecol Obstet Invest; 2007;63(3):140-2
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed clear cell and endometrioid carcinoma arising in parietal endometriosis.
  • AIM: We report a case of a mixed clear cell and endometrioid carcinoma arising in parietal endometriosis.
  • METHODS: A 46-year-old woman presented a second recurrence of parietal endometriosis.
  • RESULTS: Histological analysis revealed heterogeneous tissues including clear cell and endometrioid carcinoma fields arising from a large benign endometriosis lesion.
  • Despite chemotherapy, the patient died 6 months after the diagnosis.
  • CONCLUSIONS: Clear cell carcinoma and endometrioid carcinoma have been rarely found in parietal endometriosis.
  • Clinicians should learn to suspect a cancerous transformation of a parietal endometriosis, when rapid recurrence and extensive development are observed.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Carcinoma, Endometrioid / surgery. Cesarean Section / adverse effects. Endometriosis / surgery

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17057400.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


Advertisement
4. Akay H, Cangir AK, Kutlay H, Kavukçu S, Okten I, Yavuzer S: Surgical treatment of peripheral lung cancer adherent to the parietal pleura. Eur J Cardiothorac Surg; 2002 Oct;22(4):615-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of peripheral lung cancer adherent to the parietal pleura.
  • OBJECTIVES: The objective of this paper is to assess the results of surgical treatment retrospectively in a consecutive series of 85 patients with peripheral non-small cell lung cancer (NSCLC) invading parietal pleura and chest wall.
  • METHODS: From 1994 to 1998, of the 572 patients having pulmonary resection for NSCLC, 29 patients with neoplasm involving the parietal pleura (group I) and 56 with that invading the chest wall (group II) underwent resection.
  • Systemic chemotherapy was also administered in seven patients in group I and eight in group II.
  • There was a significant difference in adjuvant therapy between the groups (P<0.05).
  • CONCLUSIONS: We found similar survival rates for extrapleural resection in limited parietal pleura invasion and chest wall resection in exceeded-beyond-parietal pleura invasion.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12297182.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Ohta Y, Oda M, Shimizu J, Watanabe G: Multimodality treatment including parietal pleurectomy as a possible therapeutic procedure for malignant pleural effusion. Surg Technol Int; 2007;16:184-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment including parietal pleurectomy as a possible therapeutic procedure for malignant pleural effusion.
  • Long-term control of malignant pleural effusion is an important goal of therapy in patients with pleural dissemination.
  • The authors have carried out limited operations combined with parietal pleurectomy (PL) for non-small cell lung cancer patients with pleural dissemination, based on the hypothesis that the most effective target area for controlling malignant pleural effusion is the parietal pleura.
  • In our 25 years of experience, 54 patients with pleural dissemination (26 also had malignant pleural effusion) have undergone this surgical treatment.
  • Postoperative intrapleural chemotherapy and systemic chemotherapy (2-4 cycles) also were applied in 43 patients.
  • Recurrent malignant pleural effusion developed in only two of 30 patients whose recurrent patterns could be clearly identified.
  • Although this was not a clinical randomized comparative study, multimodality treatment that included the use of PL appears to be a useful option for treatment of this disease in appropriately selected patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung / surgery. Lung Neoplasms / surgery. Pleural Effusion / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17429787.001).
  • [ISSN] 1090-3941
  • [Journal-full-title] Surgical technology international
  • [ISO-abbreviation] Surg Technol Int
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Bourdel N, Durand M, Gimbergues P, Dauplat J, Canis M: Exclusive nodal recurrence after treatment of degenerated parietal endometriosis. Fertil Steril; 2010 Apr;93(6):2074.e1-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exclusive nodal recurrence after treatment of degenerated parietal endometriosis.
  • OBJECTIVE: To report a case of endometriosis degenerated into clear cell carcinoma with positron-emission tomography (PET) scan staging.
  • PATIENT(S): A 43-year-old woman diagnosed with endometriosis degenerated into clear cell carcinoma with nodal metastasis at the initial diagnosis and exclusive nodal recurrence 6 months after surgery.
  • Forty-five days later, hysterectomy with bilateral adnexectomy and then adjuvant chemotherapy and abdominal-pelvic radiotherapy.
  • After surgical management, she was scheduled to receive six cycles of rescue chemotherapy.
  • The treatment of this entity is based on radical surgery associated with adjuvant chemotherapy and radiotherapy, but the results are not satisfactory.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / complications. Peritoneal Diseases / complications. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20045513.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Wada Y, Yamamoto T, Kita Y, Fukunishi S, Ashida K: [An autopsy case of encephalopathy associated with small cell carcinoma of the stomach with nonconvulsive status epilepticus resembling Creutzfeldt-Jakob disease]. No To Shinkei; 2003 May;55(5):423-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of encephalopathy associated with small cell carcinoma of the stomach with nonconvulsive status epilepticus resembling Creutzfeldt-Jakob disease].
  • A 64-year-old man developed progressive dementia and altered consciousness with myoclonus over 2 months.
  • Electroencephalography (EEG) showed continuous periodic synchronous discharge (PSD) of 1 Hz, although his EEG abnormality was not similar to that usually observed in Creutzfeldt-Jakob disease (CJD).
  • Diffusion-weighted MRI showed a T2-hyperintense lesion in the right parietal lobe, where SPECT scans showed hyperperfusion.
  • Biopsy of the periaortic lymph node by laparotomy revealed undifferentiated adenocarcinoma with its origin being unclear.
  • Chemotherapy didn't work well for the tumor and the patient underwent a downhill course, although his mental and neurological manifestation were mostly unremarkable.
  • Autopsy confirmed small cell carcinoma originating in the stomach and metastases in the liver and lungs.
  • [MeSH-major] Brain Diseases / pathology. Carcinoma, Small Cell / complications. Creutzfeldt-Jakob Syndrome / diagnosis. Status Epilepticus / diagnosis. Stomach Neoplasms / complications


8. Matsuda R, Motoyama Y, Takeshima Y, Kimura R, Iida J, Nakamura M, Mishima H, Park YS, Hirabayashi H, Nakase H, Sakai T: [A case of brain metastasis of renal pelvic carcinoma]. No Shinkei Geka; 2009 Feb;37(2):179-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis of renal pelvic carcinoma].
  • Contrast-enhanced computed tomography (CT) revealed renal tumor and multiple lung metastases.
  • Pathological examination was transitional cell carcinoma.
  • After nephroureterectomy, combination chemotherapy consisting of methotrexate, doxorubicin and cisplatin was performed.
  • Contrast-enhanced CT of the head revealed a heterogeneous enhancement tumor in the parietal lobe.
  • Surgical resection was performed by right parietal craniotomy.
  • Pathological examination indicated transitional cell carcinoma the same feature as in the renal pelvis.
  • Brain metastasis of renal pelvic carcinoma is extremely rare, and we have found only three case reports.
  • We describe the course of our patient, and review the three cases of brain metastasis of renal pelvic carcinoma that are in the literature.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227160.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


9. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN: Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges; 2008 Dec;6(12):1066-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
  • Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide.
  • Epidermal growth factor receptor (EGFR) is expressed at the cell surface by more than 90% of SCCs and its activation is responsible for cell cycle progression, proliferation, survival, angiogenesis and metastasis.
  • An 88-year-old man presented with a recurrent, locoregionally meta-static SCC of the right parietal region, which was resistant to radiotherapy.
  • With a combination therapy of an EGFR blocker (cetuximab) and a COX-2 inhibitor (celecoxib), the tumor regressed partially and the patient's Karnofsky index improved.
  • We speculate that the combined use of cetuximab and COX-2 inhibitors can be a new and effective therapy for advanced and recurrent cutaneous SCCs.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cyclooxygenase 2 Inhibitors / administration & dosage. Pyrazoles / administration & dosage. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Skin Neoplasms / drug therapy. Sulfonamides / administration & dosage
  • [MeSH-minor] Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Celecoxib. Cetuximab. Cyclooxygenase Inhibitors / administration & dosage. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138272.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; JCX84Q7J1L / Celecoxib; PQX0D8J21J / Cetuximab
  •  go-up   go-down


10. Soprano DR, Teets BW, Soprano KJ: Role of retinoic acid in the differentiation of embryonal carcinoma and embryonic stem cells. Vitam Horm; 2007;75:69-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of retinoic acid in the differentiation of embryonal carcinoma and embryonic stem cells.
  • This chapter is a review of the mechanism of action of RA and the role of specific RA-regulated genes during the cellular differentiation of embryonal carcinoma (EC) and embryonic stem (ES) cells.
  • The most studied mouse EC cell lines include F9 cells, which can be induced by RA to differentiate into primitive, parietal, and visceral endodermal cells; and P19 cells, which can differentiate to endodermal and neuronal cells upon RA treatment.
  • ES cells can be induced to differentiate into a number of different cell types; many of which require RA treatment.
  • However, the exact molecule events that lead from a pluripotent stem cell to a fully differentiated cell following RA treatment are yet to be determined.
  • [MeSH-major] Carcinoma, Embryonal / drug therapy. Cell Differentiation / drug effects. Gene Expression Regulation, Developmental / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Stem Cells / drug effects. Tretinoin / pharmacology
  • [MeSH-minor] Animals. Humans. Mice. Transcription, Genetic / drug effects. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Embryonal Carcinoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368312.001).
  • [ISSN] 0083-6729
  • [Journal-full-title] Vitamins and hormones
  • [ISO-abbreviation] Vitam. Horm.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK070650
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  • [Number-of-references] 149
  •  go-up   go-down


11. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology of late recurrence of testicular germ cell tumors.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • Twenty percent of patients with late recurrence had a nonteratomatous germ cell tumor other than yolk sac tumor, either alone, with yolk sac tumor, or with a "nongerm cell malignant tumor."
  • Most of these nonteratomatous germ cell tumors other than yolk sac tumor were embryonal carcinoma, although rarely seminoma and choriocarcinoma were encountered.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


12. Ostoros G, Orosz Z, Kovács G, Soltész I: Desmoplastic small round cell tumour of the pleura: a case report with unusual follow-up. Lung Cancer; 2002 Jun;36(3):333-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumour of the pleura: a case report with unusual follow-up.
  • In 1994 a 19-year-old woman presented with a few weeks history of back ache.
  • Routine chest X-ray and CT examination revealed a lesion originating from the parietal pleura and destroying the ribs.
  • Three years after the initial presentation multiple pulmonary metastases developed.
  • The patient was treated with chemotherapy, receiving vincristine, epi-adriamycin and cyclophosphamide in 8 cycles, which resulted in complete remission.
  • Between 1998 and 1999 progressions and partial remissions were observed, while the patient received further cycles of chemotherapy.
  • Histological revision was performed in 1999 and a final diagnosis of desmoplastic small round cell tumour of the pleura was made.
  • We thought this case to be worth for presentation because this unusual long survival, which was probably due to the aggressive complex anticancer treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / therapy. Pleural Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12009247.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


13. Riquet M, Lang-Lazdunski L, Le PB, Dujon A, Souilamas R, Danel C, Manac'h D: Characteristics and prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg; 2002 Jan;73(1):253-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and prognosis of resected T3 non-small cell lung cancer.
  • BACKGROUND: T3 tumors can be divided into several subgroups depending on the type of anatomical structure invaded: chest wall, mediastinal pleura, or main bronchus.
  • METHODS: The results of surgical treatment were retrospectively analyzed for 261 patients with T3 non-small cell lung cancer invading either the mediastinal pleura or parietal pericardium by direct extension (mediastinal pT3, n = 68), or main bronchus (bronchial pT3, n = 68), or chest wall (chest wall pT3, n = 125) that were operated on between 1984 and 1996.
  • One hundred and fifty-eight patients received adjuvant radiation therapy and 7 patients received both adjuvant chemotherapy and radiation therapy.
  • Histology, type of surgical resection (lobectomy versus pneumonectomy), and use of adjuvant therapy did not influence survival significantly.
  • CONCLUSIONS: Five-year survival was not significantly different among the three subgroups of pT3 non-small cell lung cancer, although bronchial pT3 tumors tended to have a better prognosis and chest wall pT3 tumors tended to have a worse prognosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Female. Hospital Mortality. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11834019.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Rafii A, Ferron G, Lacroix-Triki M, Dalenc F, Gladieff L, Querleu D: Abdominal wall metastasis of ovarian carcinoma after low transverse abdominal incision: report of two cases and review of literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:334-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal wall metastasis of ovarian carcinoma after low transverse abdominal incision: report of two cases and review of literature.
  • Occurrence of parietal metastases after surgery for a suspect adnexal mass may worsen the prognosis of the disease.
  • We report two cases with development of parietal dissemination of ovarian carcinomas after Pfannenstiel incision.
  • The two patients needed parietal resection to obtain optimal surgical cytoreduction.
  • Pfannenstiel incisions for exploration of suspicious adnexal masses increase the risk of extensive parietal metastasis in case of malignancy because they require reflection of several sheaths of tissue.
  • The parietal extension of the disease may need major parietal resection that can worsen the functional and general outcome of the patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Granulosa Cell Tumor / secondary. Neoplasm Seeding. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Abdominal Wall. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Ifosfamide / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515617.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; BEP protocol
  •  go-up   go-down


15. Yurdakul AS, Halilçolar H, Oztürk C, Tatar D, Karakaya J: [Factors affecting the prognosis in patients with primary lung cancer and brain metastases]. Tuberk Toraks; 2006;54(3):235-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain metastases are frequent features during the course of patients with lung carcinoma.
  • Fifty-two (59.1%) patients had solitary brain metastasis and the most frequent metastasing site was parietal lobe (34.1%).
  • The median survival times were 3 months after diagnosis of lung carcinoma and 1.5 months after diagnosis of brain metastasis.
  • Although the absence of brain metastasis at the moment of diagnosis, metachronous metastasis, central localization of the tumour, chemotherapy administration and surgical treatment of brain metastasis are good prognostic factors affecting survival after the diagnosis of lung carcinoma, the positive factors affecting survival after brain metastasis are central localization of tumour, chemotherapy administration and surgical treatment of brain metastasis.
  • In conclusion, performing the combination of cranial radiotherapy, chemotherapy, surgical therapy and supporting therapy should be evaluated in all appropriate patients with brain metastasis from lung cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Carcinoma, Small Cell / mortality. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Turkey / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001540.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


16. Russell MT, Nassif AS, Cacayorin ED, Awwad E, Perman W, Dunphy F: Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging; 2001 Jan;19(1):129-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55 year old female receiving gemcitabine for stage IV non-small cell carcinoma of the lung developed the clinical-radiologic syndrome of posterior reversible encephalopathy syndrome (PRES).
  • The fluid-attentuated inversion recovery (FLAIR) MR imaging sequence conspicuously showed bihemispheric, symmetrical cortical and subcortical white matter hyperintensities that preponderantly involved the parietal and occipital lobes.
  • The clinical and radiologic manifestations essentially resolved completely with discontinuation of the drug.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Brain Injuries / chemically induced. Brain Injuries / pathology. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / adverse effects. Deoxycytidine / therapeutic use. Lung Neoplasms / drug therapy. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11295355.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


17. Doddoli C, D'Journo B, Le Pimpec-Barthes F, Dujon A, Foucault C, Thomas P, Riquet M: Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg; 2005 Dec;80(6):2032-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies.
  • BACKGROUND: Factors influencing survival of patients with a nonsmall-cell lung cancer (NSCLC) invading the parietal pleura or the chest wall are still controversial.
  • In stage IIB patients with a chest wall invasion limited to the parietal pleura, en-bloc resections provided higher 5-year survival rates when compared with extrapleural resections (60.3% versus 39.1%; p = 0.03).
  • In stage IIIA patients, multivariate analysis disclosed two independent prognostic factors: the number of resected ribs and adjuvant parietal and mediastinal radiotherapy.
  • For huge tumors (larger than 6 cm), this report suggests that the role of perioperative chemotherapy needs further evaluation.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Pneumonectomy / methods. Thoracic Neoplasms / pathology. Thoracic Wall

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Dec;80(6):2040 [16305840.001]
  • (PMID = 16305839.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Chapelier A, Fadel E, Macchiarini P, Lenot B, Le Roy Ladurie F, Cerrina J, Dartevelle P: Factors affecting long-term survival after en-bloc resection of lung cancer invading the chest wall. Eur J Cardiothorac Surg; 2000 Nov;18(5):513-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Several reports emphasize the importance of en-bloc resection as the optimal surgical treatment of lung cancer with chest wall invasion.
  • METHODS: Between 1981 and 1998, 100 patients (90 male; ten female), with a median age of 60 years (36-84), underwent radical en-bloc resection of non-small cell lung cancer (NSCLC) with chest wall involvement.
  • Sixty-three patients received postoperative radiotherapy and 12 received chemotherapy.
  • Chest wall invasion was limited to the parietal pleura in 29 patients and included intercostal muscles, bones and extrathoracic muscles in 67, 24 and seven cases, respectively.
  • 01) and the depth of chest wall invasion (parietal pleura vs. others; P=0.024).
  • The role of induction chemotherapy for tumors with poor prognosis should be investigated.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Carcinoma / mortality. Carcinoma / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery. Pneumonectomy / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Follow-Up Studies. Hospital Mortality. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11053809.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


19. Nguyen NC, Sayed MM, Taalab K, Osman MM: Spinal cord metastases from lung cancer: detection with F-18 FDG PET/CT. Clin Nucl Med; 2008 May;33(5):356-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord metastases from lung cancer: detection with F-18 FDG PET/CT.
  • She underwent a left upper lobectomy in June 2005 revealing moderately poorly differentiated adenocarcinoma (pT3N0M0) and subsequent chemotherapy completed December 2005.
  • Nine months later, a left parietal lobe metastatic lesion was surgically resected.
  • Clinically, the patient recently developed back pain without evidence of neurologic deficits.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / secondary. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Lumbar Vertebrae / radiography. Lumbar Vertebrae / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Thoracic Vertebrae / radiography. Thoracic Vertebrae / radionuclide imaging. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431157.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Marchevsky AM: Problems in pathologic staging of lung cancer. Arch Pathol Lab Med; 2006 Mar;130(3):292-302
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is used by thoracic surgeons, radiation therapists, and oncologists to determine whether patients with these neoplasms will be treated surgically with curative intent or with palliative radiation therapy and/or chemotherapy.
  • DATA SOURCES: Potential practical difficulties that can arise during the pathologic staging of lung cancer patients include the distinction between pT1, pT2, and pT3 lesions based on their location and the presence of visceral pleura and/or parietal pleura invasion; the differential diagnosis between multiple synchronous or metachronous primary lung neoplasms (pT1m) and intrapulmonary metastasis of non-small cell carcinoma of the lung (pT4 or pM1 according to their location); and the role of the recent American Joint Committee on Cancer terminology for the classification of lymph nodes (isolated tumor cells, micrometastases, and metastases).
  • A brief discussion of the assessment of the effects of neoadjuvant therapy on resected lung neoplasms is also included.

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519556.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Stoelben E, Ludwig C: Chest wall resection for lung cancer: indications and techniques. Eur J Cardiothorac Surg; 2009 Mar;35(3):450-6
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If the lung is not adherent to the parietal pleura, a standard lobectomy can be performed.
  • We do not want to perform over-treatment since lung resection en bloc with the chest wall has a higher morbidity and mortality than lobectomy.
  • The use of modern pain treatment is very important.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Pancoast Syndrome / surgery. Thoracic Wall / surgery
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis / pathology. Male. Neoplasm Invasiveness. Neoplasm Staging. Pain, Postoperative / drug therapy. Pleura / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188079.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 38
  •  go-up   go-down


22. Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J: Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology; 2005 Jun;128(7):1937-52
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice.
  • BACKGROUND & AIMS: The impact of Helicobacter eradication therapy on the progression or regression of gastric lesions is poorly defined.
  • This study examined the effects of eradication therapy on inflammation, atrophy, metaplasia, dysplasia, and cancer progression.
  • METHODS: C57BL/6 mice were infected with Helicobacter felis and received bacterial eradication therapy after 2, 6, or 12 months of infection.
  • The gastric mucosa was examined at early, mid, and late intervals after eradication and graded for histology, expression pattern of alpha-catenin and beta-catenin, and IQGAP1.
  • RESULTS: Eradication of Helicobacter infection after 2 or 6 months of infection led to a regression of inflammation, restoration of parietal cell mass, and reestablishment of normal architecture.
  • Progression to adenocarcinoma was prevented.
  • Bacterial eradication at 1 year was associated with the reappearance of parietal cells, partial regression of inflammation, and restoration of architecture.
  • Infected mice developed antral adenocarcinoma and gastric outlet obstruction by 24 months.
  • Only 30% of the mice receiving bacterial eradication therapy at 12 months developed antral carcinoma.
  • Bacterial eradication at any time during the first year of infection prevented death due to gastric outlet obstruction.
  • The expression pattern of alpha-catenin, beta-catenin, and IQGAP1 varied with cell type and paralleled histologic changes.
  • CONCLUSIONS: Inflammation, metaplasia, and dysplasia are reversible with early eradication therapy; progression of dysplasia was arrested with eradication therapy given as late as 1 year and prevented gastric cancer-related deaths.
  • [MeSH-major] Adenocarcinoma / microbiology. Helicobacter Infections / drug therapy. Helicobacter felis / pathogenicity. Precancerous Conditions / microbiology. Stomach Neoplasms / microbiology
  • [MeSH-minor] Animals. Anti-Bacterial Agents / therapeutic use. Atrophy. Disease Models, Animal. Gastric Mucosa / immunology. Gastric Mucosa / pathology. Male. Mice. Mice, Inbred C57BL. Tetracycline / therapeutic use

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TETRACYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940628.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K22 CA96485
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; F8VB5M810T / Tetracycline
  •  go-up   go-down






Advertisement